Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medicaid Work Requirements
  • ‘Skinny Labeling’
  • Gun Control
  • Suicide Prevention
  • Rural Health Payout

TRENDING TOPICS:

  • Medicaid Work Requirements
  • 'Skinny Labeling'
  • Gun Control
  • Suicide Prevention
  • Rural Health Payout

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, Jul 16 2018

Full Issue

Novartis Issued Misleading Statements About Duration Of Relationship With Michael Cohen, Emails Show

The existence of the agreement between the drugmaker and President Donald Trump's personal attorney Michael Cohen -- whose consulting firm was paid $1.2 million from early 2017 through early 2018 -- first became known months ago. At the time, Novartis portrayed the arrangement as a brief interaction. But emails and other documents show otherwise.

Stat: Novartis, Michael Cohen Contacts More Extensive Than Disclosed Earlier

The relationship between President Trump’s personal attorney, Michael Cohen, and Novartis was more extensive than the drug maker previously disclosed, and the company issued misleading statements about the relationship, according to a report issued by Senate Democrats on Friday. Dozens of emails and other documents revealed that the agreement between Cohen and Novartis was longer and more detailed than had been previously stated. Moreover, Novartis explicitly sought to hire Cohen to gain access to “key policymakers” and provided him with ideas for lowering drug costs, which later appeared in the Trump administration blueprint that was developed to address the issue. (Silverman, 7/13)

The Wall Street Journal: Novartis Played Down Ties To Trump Lawyer Michael Cohen, Report Says

The report also reveals Mr. Cohen’s advocacy for another pharmaceutical company, one the report says has ties to an investment firm associated with Viktor Vekselberg, a wealthy Russian businessman now under U.S. sanctions. The $1.2 million consulting deal with Novartis came to light in May. Then the Switzerland-based drug company said it hired Mr. Cohen for insight into how “the Trump administration might approach U.S. health-care policy matters,” but that executives realized from their first meeting with him in March 2017 that he wouldn’t be helpful and stopped engaging with him. (Palazzolo and Rothfeld, 7/13)

Politico Pro: Drugmaker's Ties With Michael Cohen More Extensive Than Detailed, Report Says

Dozens of emails and other documents obtained by the Democrats showed that Cohen worked with Novartis for six months longer than the company said in May, a period during which he pitched executives on investing in a pharmaceutical company backed by investment firm Columbus Nova. The firm is linked to Russian oligarch Viktor Vekselberg, who was sanctioned last month over Russia's meddling in the U.S. election. (Cancryn and Karlin-Smith, 7/13)

Stat: Novartis Needed A Consultant. The CEO's Friend Called Trump's Lawyer

Shortly after the 2016 election, Novartis chief executive Joe Jimenez was looking for a consultant to help understand how the Trump administration would approach health policy. So, when a friend suggested Trump lawyer Michael Cohen, Jimenez took the call, and personally suggested following up, according to a letter Novartis sent to senators in June and publicly released Friday. (Swetlitz, 7/13)

The Hill: Ex-Novartis CEO Sent Drug Pricing Proposal To Cohen

In an email dated June 5, 2017, ex-Novartis CEO Joe Jimenez sent Cohen an email with a document attached called "drug pricing initiatives." "Based on our conversation last week, I am forwarding you some ideas to lower drug costs in the US," Jimenez wrote. Cohen responded a few hours later: "Received and I will forward to you their suggestions." (Hellmann, 7/13)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 30
  • Wednesday, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF